Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Phase 0 trials: expediting the development of chemoprevention agents.

Kummar S, Doroshow JH.

Cancer Prev Res (Phila). 2011 Mar;4(3):288-92. doi: 10.1158/1940-6207.CAPR-11-0013.

2.

The next phase of chemoprevention research.

Cohen EE, Schilsky RL.

Cancer Prev Res (Phila). 2011 Mar;4(3):293-5. doi: 10.1158/1940-6207.CAPR-11-0012.

3.

Curcumin chemoprevention: the long road to clinical translation.

Shureiqi I, Baron JA.

Cancer Prev Res (Phila). 2011 Mar;4(3):296-8. doi: 10.1158/1940-6207.CAPR-11-0060.

4.

Food extracts for chemoprevention: quo vadis?

Meyskens FL Jr.

Cancer Prev Res (Phila). 2009 Jul;2(7):608-10. doi: 10.1158/1940-6207.CAPR-09-0102. No abstract available.

5.

Phase 0 clinical chemoprevention trial of the Akt inhibitor SR13668.

Reid JM, Walden CA, Qin R, Ziegler KL, Haslam JL, Rajewski RA, Warndahl R, Fitting CL, Boring D, Szabo E, Crowell J, Perloff M, Jong L, Bauer BA, Mandrekar SJ, Ames MM, Limburg PJ; Cancer Prevention Network.

Cancer Prev Res (Phila). 2011 Mar;4(3):347-53. doi: 10.1158/1940-6207.CAPR-10-0313.

6.

Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.

Greenwald P.

J Cell Biochem Suppl. 1996;25:29-36. Review.

PMID:
9027595
7.

Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations.

Lieberman R, Nelson WG, Sakr WA, Meyskens FL Jr, Klein EA, Wilding G, Partin AW, Lee JJ, Lippman SM.

Urology. 2001 Apr;57(4 Suppl 1):4-27.

PMID:
11295590
8.

Phase 0 clinical trials: conceptions and misconceptions.

Kummar S, Rubinstein L, Kinders R, Parchment RE, Gutierrez ME, Murgo AJ, Ji J, Mroczkowski B, Pickeral OK, Simpson M, Hollingshead M, Yang SX, Helman L, Wiltrout R, Collins J, Tomaszewski JE, Doroshow JH.

Cancer J. 2008 May-Jun;14(3):133-7. doi: 10.1097/PPO.0b013e318172d6f3. Review.

PMID:
18536551
9.

Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.

Kinders R, Parchment RE, Ji J, Kummar S, Murgo AJ, Gutierrez M, Collins J, Rubinstein L, Pickeral O, Steinberg SM, Yang S, Hollingshead M, Chen A, Helman L, Wiltrout R, Simpson M, Tomaszewski JE, Doroshow JH.

Mol Interv. 2007 Dec;7(6):325-34. doi: 10.1124/mi.7.6.9. Review.

PMID:
18199854
10.

Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.

Kelloff GJ, Boone CW, Steele VE, Crowell JA, Lubet R, Sigman CC.

Cancer Res. 1994 Apr 1;54(7 Suppl):2015s-2024s. Review.

11.

Chemoprevention clinical trials.

Kelloff GJ, Boone CW, Malone WF, Steele VE.

Mutat Res. 1992 Jun;267(2):291-5. Review.

PMID:
1376431
12.

Exploratory IND: a new regulatory strategy for early clinical drug development in the United States.

Sarapa N.

Ernst Schering Res Found Workshop. 2007;(59):151-63. Review.

PMID:
17117721
13.

How should we move the field of chemopreventive agent development forward in a productive manner?

Meyskens FL, Szabo E.

Recent Results Cancer Res. 2005;166:113-24. Review.

PMID:
15648187
14.

Chemoprevention of human cancer: a reasonable strategy?

Meyskens FL Jr.

Recent Results Cancer Res. 1999;151:113-21. Review.

PMID:
10337722
15.

5-α reductase inhibitors and prostate cancer prevention: where do we turn now?

Hamilton RJ, Freedland SJ.

BMC Med. 2011 Sep 15;9:105. doi: 10.1186/1741-7015-9-105.

16.

Progress in clinical chemoprevention.

Kelloff GJ, Hawk ET, Karp JE, Crowell JA, Boone CW, Steele VE, Lubet RA, Sigman CC.

Semin Oncol. 1997 Apr;24(2):241-52. Review.

PMID:
9129692
17.

Cancer chemoprevention: progress and promise.

Kelloff GJ, Sigman CC, Greenwald P.

Eur J Cancer. 1999 Dec;35(13):1755-62. Review.

PMID:
10673988
18.

Is it time to advance the chemoprevention of environmental carcinogenesis with microdosing trials?

Kensler TW, Groopman JD.

Cancer Prev Res (Phila). 2009 Dec;2(12):1003-7. doi: 10.1158/1940-6207.CAPR-09-0232. Epub 2009 Dec 1.

19.

Criteria of evidence to move potential chemopreventive agents into late phase clinical trials.

Kelly RJ, Lopez-Chavez A, Szabo E.

Curr Drug Targets. 2011 Dec;12(13):1983-8. Review.

PMID:
21158704
20.

Trial endpoints for drug approval in oncology: Chemoprevention.

Beitz J.

Urology. 2001 Apr;57(4 Suppl 1):213-5.

PMID:
11295630

Supplemental Content

Support Center